Lineage Cell Therapeutics... (LCTX)
| Bid | 0.4 |
| Market Cap | 93.63M |
| Revenue (ttm) | 9.5M |
| Net Income (ttm) | -18.61M |
| EPS (ttm) | -0.09 |
| PE Ratio (ttm) | -4.56 |
| Forward PE | -6.92 |
| Analyst | Buy |
| Ask | 0.47 |
| Volume | 1,207,276 |
| Avg. Volume (20D) | 1,547,270 |
| Open | 0.41 |
| Previous Close | 0.42 |
| Day's Range | 0.41 - 0.44 |
| 52-Week Range | 0.37 - 1.40 |
| Beta | 1.33 |
About LCTX
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy that is in Phase I/IIa mul...
Analyst Forecast
According to 5 analyst ratings, the average rating for LCTX stock is "Buy." The 12-month stock price forecast is $3, which is an increase of 631.71% from the latest price.
Stock ForecastsNext Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago · seekingalpha.com
Lineage Cell Therapeutics, Inc. (LCTX) Q4 2024 Earnings Call TranscriptLineage Cell Therapeutics, Inc. (NYSE:LCTX ) Q4 2024 Earnings Conference Call March 10, 2025 4:30 PM ET Company Participants Ioana Hone - Head of Investor Relations Brian Culley - Chief Executive Offi...
